慢性丙型肝炎患者直接抗病毒治疗的疗效

One Health Risk Management Pub Date : 2020-03-31 DOI:10.38045/ohrm.2020.1.02

I. Rusu, Liliana Hodorogea, T. Holban

{"title":"慢性丙型肝炎患者直接抗病毒治疗的疗效","authors":"I. Rusu, Liliana Hodorogea, T. Holban","doi":"10.38045/ohrm.2020.1.02","DOIUrl":null,"url":null,"abstract":"assessment of hepatitis C and genotype, as well as the degree of hepatic fibrosis by Fibroscan, biochemical and complete blood count indices carried out. Results. The study results showed high efficacy of the generic DAAs treatment in patients with chronic HCV over 12 weeks. The SVR rate made up 90.3% in Sofosbuvir + Ledipasvir therapy and","PeriodicalId":34509,"journal":{"name":"One Health Risk Management","volume":"23 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C\",\"authors\":\"I. Rusu, Liliana Hodorogea, T. Holban\",\"doi\":\"10.38045/ohrm.2020.1.02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"assessment of hepatitis C and genotype, as well as the degree of hepatic fibrosis by Fibroscan, biochemical and complete blood count indices carried out. Results. The study results showed high efficacy of the generic DAAs treatment in patients with chronic HCV over 12 weeks. The SVR rate made up 90.3% in Sofosbuvir + Ledipasvir therapy and\",\"PeriodicalId\":34509,\"journal\":{\"name\":\"One Health Risk Management\",\"volume\":\"23 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"One Health Risk Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.38045/ohrm.2020.1.02\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"One Health Risk Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.38045/ohrm.2020.1.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

采用纤维扫描(Fibroscan)、生化及全血细胞计数等指标评估丙型肝炎及基因型及肝纤维化程度。结果。研究结果显示，通用DAAs治疗慢性HCV患者超过12周的疗效很高。索非布韦+来地帕韦治疗的SVR率为90.3%

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C

assessment of hepatitis C and genotype, as well as the degree of hepatic fibrosis by Fibroscan, biochemical and complete blood count indices carried out. Results. The study results showed high efficacy of the generic DAAs treatment in patients with chronic HCV over 12 weeks. The SVR rate made up 90.3% in Sofosbuvir + Ledipasvir therapy and

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

One Health Risk Management

CiteScore

0.20

自引率

0.00%

发文量

审稿时长

10 weeks